Healthcare

Results offers the skills of an experienced and entrepreneurial healthcare team dedicated to the life sciences sector having closed more than 75 successful transactions to date. Our clients trust us because of our strong international relationships with shareholders and management teams across the healthcare lifecycle. We combine expert financial capabilities with backgrounds in science, healthcare and IT that will bring value to your business.

We work with businesses and entrepreneurs to help articulate the ideal equity story, target the right investors and negotiate the best deal.

• Full service offering for Healthcare M&A transactions, for both buyers and sellers
• Advice on strategic options for healthcare businesses and assets
• Expert guidance on development capital, utilisation of investments or finance for MBO/MBI
• Support for licensing transactions for research assets and marketed products

Healthcare Sub-Sectors

Our highly specialised, global team works together seamlessly across six focus areas in the healthcare sector.

Healthcare Deals

May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monocloncal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Mar 2022
has divested its Boucherville, Canada manufacturing facility
Feb 2022
has received investment from
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Nov 2021
has received investment from
Nov 2021
has made an investment in
company name confidential
Aug 2021
has been acquired by
an Odyssey Investment Partners-backed company
Aug 2021
a Sovereign Capital Partners-backed company
has acquired
Aug 2021
a Sovereign Capital Partners-backed company
has acquired

Latest Insights

Insights
24th May 2022

Crossrail opens – a big day for travellers to and workers in London

At Results Healthcare we execute transactions around the world, with active projects in North America, Europe and Asia Pacific, so we see ourselves as a global organisation with offices and employees in London and New York, so a blog on transport in London might seem oddly parochial, but the opening of Crossrail, or the Elizabeth […]

Insights
29th March 2022

DCAT’s Back / Back at DCAT

For the first time in forever it felt like the good old days were back in midtown Manhattan at everyone’s favourite pharma supply chain conference The hotels. The meetings. The dinners. Walking up and down Lexington Avenue and bumping into friends and colleagues. It was all happening again at DCAT last week in New York. […]

Insights
28th March 2022

The growing impact of Environmental, Social, and Governance (“ESG”) on pharmaceutical supply chains.

The Russian invasion of Ukraine has been touted as the final nail in the coffin of globalisation, confirming the nationalisation of key industries and products. With respect to pharmaceutical manufacturing, this is accelerating a trend which has been ongoing for 10 years, the repatriation of drug manufacturing from Asia to the US and Europe has […]